9 Meters Biopharma, Inc. (NMTR)

$0.2249

-0.04 (-13.77%)
Rating:
Recommendation:
-
Symbol NMTR
Price $0.2249
Beta 0.343
Volume Avg. 3.11M
Market Cap 58.273M
Shares () -
52 Week Range 0.221-1.46
1y Target Est -
DCF Unlevered NMTR DCF ->
DCF Levered NMTR LDCF ->
ROE -94.39% Strong Sell
ROA -108.75% Strong Sell
Operating Margin -
Debt / Equity 26.90% Neutral
P/E -
P/B 1.88 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NMTR news


Mr. John Temperato
Healthcare
Biotechnology
NASDAQ Capital Market

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.